119 related articles for article (PubMed ID: 36314339)
1. The potential prognostic novel markers PIV and PILE score to predict survival outcomes at hepatocellular cancer.
Karadağ I; Karakaya S; Yılmaz ME; Çakmak Öksüzoğlu ÖB
Eur Rev Med Pharmacol Sci; 2022 Oct; 26(20):7679-7686. PubMed ID: 36314339
[TBL] [Abstract][Full Text] [Related]
2. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
Front Immunol; 2021; 12():724443. PubMed ID: 34777341
[TBL] [Abstract][Full Text] [Related]
3. PILE: a candidate prognostic score in cancer patients treated with immunotherapy.
Guven DC; Yildirim HC; Bilgin E; Aktepe OH; Taban H; Sahin TK; Cakir IY; Akin S; Dizdar O; Aksoy S; Yalcin S; Erman M; Kilickap S
Clin Transl Oncol; 2021 Aug; 23(8):1630-1636. PubMed ID: 33586122
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors.
Yazgan SC; Yekedüz E; Utkan G; Ürün Y
Prostate; 2022 Nov; 82(15):1456-1461. PubMed ID: 35899494
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of pan-immune-inflammation value (PIV) in nasopharyngeal carcinoma patients.
Zhang N; Hou T; Zhang S; Ling J; Jiang S; Xie Y; Liu X; Hu C; Feng Y
Heliyon; 2024 Jan; 10(2):e24804. PubMed ID: 38312571
[TBL] [Abstract][Full Text] [Related]
6. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
7. Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas.
Topkan E; Selek U; Kucuk A; Pehlivan B
J Inflamm Res; 2022; 15():5413-5423. PubMed ID: 36158517
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
[No Abstract] [Full Text] [Related]
9. Pan‑immune‑inflammation value as a novel prognostic biomarker in nasopharyngeal carcinoma.
Su Z; Tang J; He Y; Zeng WH; Yu Q; Cao XL; Zou GR
Oncol Lett; 2024 Jun; 27(6):252. PubMed ID: 38646495
[TBL] [Abstract][Full Text] [Related]
10. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study.
Yekedüz E; Tural D; Ertürk İ; Karakaya S; Erol C; Ercelep Ö; Arslan Ç; Sever ÖN; Kılıçkap S; Şentürk Öztaş N; Küçükarda A; Can O; Öksüzoğlu B; Şendur MA; Karadurmuş N; Ürün Y
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3537-3546. PubMed ID: 35616728
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
12. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Hong YM; Yoon KT; Cho M
BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
[TBL] [Abstract][Full Text] [Related]
13. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management.
Faloppi L; Scartozzi M; Bianconi M; Svegliati Baroni G; Toniutto P; Giampieri R; Del Prete M; De Minicis S; Bitetto D; Loretelli C; D'Anzeo M; Benedetti A; Cascinu S
BMC Cancer; 2014 Feb; 14():110. PubMed ID: 24552144
[TBL] [Abstract][Full Text] [Related]
14. High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer.
Topkan E; Kucuk A; Ozkan EE; Ozturk D; Besen AA; Mertsoylu H; Pehlivan B; Selek U
Discov Oncol; 2023 Dec; 14(1):230. PubMed ID: 38091179
[TBL] [Abstract][Full Text] [Related]
15. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
16. Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C).
Goswami P; Adeniran OR; K Frantz S; Matsuoka L; Du L; Gandhi RT; Collins ZS; Matrana MR; Petroziello M; Brower JS; Sze DY; Kennedy AS; Golzarian J; Wang EA; Brown DB
BMC Gastroenterol; 2022 Nov; 22(1):467. PubMed ID: 36396989
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of pan-immune-inflammation value and body mass index in geriatric patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first line treatment. A single-center retrospective study.
Domański P; Jarosińska J; Kruczyk B; Piętak M; Mydlak A; Demkow T; Kuncman Ł; Darewicz M; Sikora-Kupis B; Michalski W; Kucharz J
Contemp Oncol (Pozn); 2023; 27(4):242-248. PubMed ID: 38405212
[TBL] [Abstract][Full Text] [Related]
18. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
[TBL] [Abstract][Full Text] [Related]
19. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
20. Role of Laparotomy-based Parameters in Assessment of Optimal Primary Debulking Surgery and Long-term Outcomes in Patients with Stage IIIC Epithelial Ovarian Cancer.
Zhou M; Wang D; Long Z; Zhang Y; Liu J
J Cancer; 2020; 11(4):983-989. PubMed ID: 31949501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
